Literature Overview of the IL-17 Inhibition from Psoriasis to COVID-19

Yulin Zou, Zudong Meng Department of Dermatology, Renmin Hospital, Hubei University of Medicine, Shiyan City, People’s Republic of ChinaCorrespondence: Zudong Meng Email zylmch1007@hbmu.edu.cnAbstract: The COVID-19 pandemic has posed a serious problem for drug anti-viral efficacy in combat...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Zou Y, Meng Z
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2021
Materias:
Acceso en línea:https://doaj.org/article/c17d6b59e6564653a2e5d1bde94e5ef0
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:c17d6b59e6564653a2e5d1bde94e5ef0
record_format dspace
spelling oai:doaj.org-article:c17d6b59e6564653a2e5d1bde94e5ef02021-12-02T19:37:59ZLiterature Overview of the IL-17 Inhibition from Psoriasis to COVID-191178-7031https://doaj.org/article/c17d6b59e6564653a2e5d1bde94e5ef02021-11-01T00:00:00Zhttps://www.dovepress.com/literature-overview-of-the-il-17-inhibition-from-psoriasis-to-covid-19-peer-reviewed-fulltext-article-JIRhttps://doaj.org/toc/1178-7031Yulin Zou, Zudong Meng Department of Dermatology, Renmin Hospital, Hubei University of Medicine, Shiyan City, People’s Republic of ChinaCorrespondence: Zudong Meng Email zylmch1007@hbmu.edu.cnAbstract: The COVID-19 pandemic has posed a serious problem for drug anti-viral efficacy in combatting the cytokine storm triggered by SARS-CoV-2. From dermato-epidemiological studies conducted on psoriatic and other rheumatological patients, IL-17 inhibitors seem to attenuate or even prevent the cytokine storm and thus ICU referral. Furthermore, both in-vivo and in-vitro experiments suggest that IL-17 plays a key role in SARS-CoV-2 infection progression. Due to this evidence, we decided to summarize the literature findings on IL-17 inhibitors and COVID-19, maintaining psoriasis as the referral disease to better understand the extent of drug effects on the immune system.Keywords: biologics, COVID-19, psoriasis, therapy, IL-17Zou YMeng ZDove Medical Pressarticlebiologicscovid-19psoriasistherapyil-17PathologyRB1-214Therapeutics. PharmacologyRM1-950ENJournal of Inflammation Research, Vol Volume 14, Pp 5611-5618 (2021)
institution DOAJ
collection DOAJ
language EN
topic biologics
covid-19
psoriasis
therapy
il-17
Pathology
RB1-214
Therapeutics. Pharmacology
RM1-950
spellingShingle biologics
covid-19
psoriasis
therapy
il-17
Pathology
RB1-214
Therapeutics. Pharmacology
RM1-950
Zou Y
Meng Z
Literature Overview of the IL-17 Inhibition from Psoriasis to COVID-19
description Yulin Zou, Zudong Meng Department of Dermatology, Renmin Hospital, Hubei University of Medicine, Shiyan City, People’s Republic of ChinaCorrespondence: Zudong Meng Email zylmch1007@hbmu.edu.cnAbstract: The COVID-19 pandemic has posed a serious problem for drug anti-viral efficacy in combatting the cytokine storm triggered by SARS-CoV-2. From dermato-epidemiological studies conducted on psoriatic and other rheumatological patients, IL-17 inhibitors seem to attenuate or even prevent the cytokine storm and thus ICU referral. Furthermore, both in-vivo and in-vitro experiments suggest that IL-17 plays a key role in SARS-CoV-2 infection progression. Due to this evidence, we decided to summarize the literature findings on IL-17 inhibitors and COVID-19, maintaining psoriasis as the referral disease to better understand the extent of drug effects on the immune system.Keywords: biologics, COVID-19, psoriasis, therapy, IL-17
format article
author Zou Y
Meng Z
author_facet Zou Y
Meng Z
author_sort Zou Y
title Literature Overview of the IL-17 Inhibition from Psoriasis to COVID-19
title_short Literature Overview of the IL-17 Inhibition from Psoriasis to COVID-19
title_full Literature Overview of the IL-17 Inhibition from Psoriasis to COVID-19
title_fullStr Literature Overview of the IL-17 Inhibition from Psoriasis to COVID-19
title_full_unstemmed Literature Overview of the IL-17 Inhibition from Psoriasis to COVID-19
title_sort literature overview of the il-17 inhibition from psoriasis to covid-19
publisher Dove Medical Press
publishDate 2021
url https://doaj.org/article/c17d6b59e6564653a2e5d1bde94e5ef0
work_keys_str_mv AT zouy literatureoverviewoftheil17inhibitionfrompsoriasistocovid19
AT mengz literatureoverviewoftheil17inhibitionfrompsoriasistocovid19
_version_ 1718376349598482432